Minotab (Minocycline Hydrochloride)

Minocycline exerts its antibacterial effect by binding to the 30S subunit of bacterial ribosomes. This blocks the addition of aminoacyl‑tRNA to the growing peptide chain, halting protein synthesis and producing a bacteriostatic effect against a broad range of Gram‑positive and Gram‑negative organisms.

The appropriate dose of Minotab is determined by the prescribing clinician based on the specific infection, its severity, patient age, weight, renal and hepatic function, and any concomitant medications. Dosage regimens are individualized and should follow the prescriber’s instructions.

Minotab is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be used in pregnancy only when the potential benefit justifies the risk. Minocycline is excreted in breast milk; breastfeeding is generally not recommended unless the benefit outweighs potential harm.

To order Minotab, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Minotab (minocycline) and doxycycline belong to the tetracycline class and share a similar mechanism of action. Minocycline generally has higher tissue penetration and a longer half‑life, allowing once‑ or twice‑daily dosing, but it may be associated with a higher incidence of vestibular side effects compared with doxycycline.

Minotab tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct heat. Keep the product out of reach of children and avoid exposure to excessive humidity, which could affect tablet integrity.

Minotab is taken orally with a full glass of water. It may be taken with or without food, but if gastrointestinal upset occurs, it can be taken with meals. Patients should follow the prescriber’s dosing schedule and avoid crushing or chewing the tablets unless instructed otherwise.

Serious adverse reactions include Stevens‑Johnson syndrome or toxic epidermal necrolysis, drug‑induced hepatitis, pseudotumor cerebri (increased intracranial pressure), and severe allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they develop rash, jaundice, severe headache, visual changes, or breathing difficulties.

Minotab should be avoided in patients with known hypersensitivity to minocycline or other tetracyclines, in those with severe hepatic impairment, and in pregnant women unless the benefit outweighs the risk. Caution is also advised for individuals with renal dysfunction, a history of intracranial hypertension, or those taking interacting medications listed under major interactions.